Search by CAS No , Chemical Name or Molecular Formula
Long Term Storage
"Nilutamide (brand names Nilandron (US), Anandron (CA)) is a synthetic, non-steroidal antiandrogen (NSAA) used in the treatment of advanced-stage (metastatic) prostate cancer. It was developed by Roussel, first introduced in 1987 (in Europe) and was the second NSAA to be marketed, with flutamide preceding it and bicalutamide following it in 1995. It was not introduced until 1996 in the United States. Because most prostate cancer cells rely on activation of the androgen receptor (AR) for growth and survival, nilutamide can slow the progression of the disease and extend life in men with prostate cancer.
Nilutamide shows unique and unfavorable tolerability and toxicity profiles, most importantly a high incidence of interstitial pneumonitis (which can progress to pulmonary fibrosis, a potentially fatal condition), and this has limited its clinical use. From a safety standpoint, bicalutamide is clinically preferred not only over nilutamide (due primarily to its risk of interstitial pneumonitis) but also flutamide (due to its high risk of hepatotoxicity) in choice of NSAA.",""
Nilutamide is a synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent grow
O'Donnell, M., et al.: J. Pharmcol. Exp. Ther., 259, 751 (1991), Jones, T., et al.: J. Physiol. Pharmcol., 73, 191 (1995), Kawano, T., et al.: J. Allergyclin. Immunol., 112, 369 (2003),
We normally respond within 8 hours.
This page contains information about Nilutamide Cas # 63612-50-0 and its API Standards.
Nilutamide Nilutamide Worldwide Suppliers of Nilutamide https://www.clearsynth.com/en/CSO30698.html API Standards Clearsynth 63612-50-0
Product rating: 9 Nilutamide based on 20 ratings
Keywords: API Standards CS-O-30698 Nilutamide Nilutamide 63612-50-0 317.22 C12H10F3N3O4
Internal standard, Internal standard Nilutamide, HPLC-MS method validation, HPLC-MS method validation Nilutamide, LC-MS-MS method validation, LC-MS-MS method validation Nilutamide, Deuterated internal standard, Deuterated internal standard Nilutamide, Deuterated Nilutamide, Deuterium labeled Nilutamide, Quantitative bioanalytical methods, Quantitative bioanalytical methods Nilutamide, Blood samples Nilutamide, Blood concentrations, Heavy drugs, Analysis, Analysis Nilutamide, Clinical diagnostic, Clinical diagnostic Nilutamide, Dosing Nilutamide, Analytical method development, Internal standard method.
CLEARSYNTH CANADA INC.
2395 Speakman Drive,
Lab: 1001, Mississauga, ON,
Canada L5K 1B3
T : +1-289-729-0060
CLEARSYNTH RESEARCH CENTRE
Plot No. 177, IDA, Mallapur,
T : +91-40-27155481
CLEARSYNTH LABS LTD
17, Lotus Business Park,
Andheri (W), Mumbai - 400053
T : +91-22-45045945